{
    "nctId": "NCT05142787",
    "briefTitle": "Magseed Pro(R)/ Sentimag(R) Gen3",
    "officialTitle": "A Prospective, Multi Center, International, Open Label Study of the Use of Magseed Pro(R) Markers and Sentimag(R) Gen3 to Localize Breast Lesions and Suspicious/biopsy-proven Positive Lymph Nodes in Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 224,
    "primaryOutcomeMeasure": "The primary endpoints are the retrieval rates of the Magseed Pro\u00ae marker with the target lesion within the initial excised specimen for A.) axillary lymph nodes B.) breast lesions A.) axillary lymph nodes. B.) breast lesions",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Participant is aged 18 years or older at the time of consent.\n* Patients requiring breast lesion/axillary node marking and excision\n\nExclusion Criteria:\u2022 Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. A pregnancy test is required for all women of childbearing potential within 7 days before enrolment.\n\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results\n* Known hypersensitivity to Nitinol\n* Subject has current active infection at the implantation site in the breast (per investigator discretion)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}